BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:03:58 AM | Browse: 409 | Download: 2107
 |
Received |
|
2022-03-17 15:25 |
|
Peer-Review Started |
|
2022-03-17 15:27 |
|
First Decision by Editorial Office Director |
|
2022-05-12 00:39 |
|
Return for Revision |
|
2022-05-12 00:39 |
|
Revised |
|
2022-05-19 10:59 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-06-20 03:01 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-06-26 22:27 |
|
Articles in Press |
|
2022-06-26 22:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-13 02:19 |
|
Publish the Manuscript Online |
|
2022-07-22 07:03 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Control Study |
| Article Title |
Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qian-Qian Wang, Yuan-Chen Zhou, Yu-Jia Zhou Ge, Geng Qin, Teng-Fei Yin, Dong-Yan Zhao, Chang Tan and Shu-Kun Yao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Development Plan for Precision Medicine Research |
2017YFC0910002 |
|
| Corresponding Author |
Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com |
| Key Words |
Precision treatment; Therapeutic target; Prognostic biomarker; Cyclin-dependent kinase inhibitor 2A; Proteomic analysis; Colorectal cancer |
| Core Tip |
In this study, quantitative proteomic analysis of colorectal cancer (CRC) was comprehensively performed, revealing many differentially expressed proteins that may be useful for mining novel targets. The results revealed the overexpression of thousands of tumor proteins, among which cyclin-dependent kinase inhibitor 2A (CDKN2A) was the highlight of this study, and high CDKN2A expression in CRC was significantly associated with poor prognosis and could serve as a powerful prognostic marker and precision therapeutic target. |
| Publish Date |
2022-07-22 07:03 |
| Citation |
Wang QQ, Zhou YC, Zhou Ge YJ, Qin G, Yin TF, Zhao DY, Tan C, Yao SK. Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer. World J Clin Cases 2022; 10(22): 7686-7697 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i22/7686.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i22.7686 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
